Technology

Technology
Anti-cancer therapy with PD1 antibody

NEXAVANT® for anticancer therapy

A

B

C

D

Figure A, B, C, D. A combination of anti-PD-1 antibody therapy with Nexavant shows an improved anti-tumor effect.

E

F

Figure E, F. Improved anti-cancer efficacy by the combined treatment of Nexavant with Nivolumab (a human anti-PD-1 antibody) was tested in the transgenic mice expressing a chimeric PD-1 with the extracellular domain of human PD-1 and the transmembrane and cytoplasmic domains of mouse PD-1 compared with the respective monotherapies.